Patient characteristics
| . | Median or count . | Range or percentage . |
|---|---|---|
| Sex, female | 21/57 | 36.8% |
| Age at diagnosis, y | 60 | 40-78 |
| β2 microglobulin at diagnosis >3, mg/L | 19/46 | 41.3% |
| Age at biopsy, y | 62 | 41-83 |
| Familial history of WM | 3/57 | 5.3% |
| Splenomegaly | 13/57 | 22.8% |
| Lymphadenopathy | 30/57 | 52.6% |
| Bone marrow involvement, % | 60 | 5-95 |
| Hemoglobin, g/dL | 11.1 | 8.2-14.5 |
| Serum IgM, mg/dL | 3750 | 416-8320 |
| Serum IgG, mg/dL | 517 | 82-3890 |
| Serum IgA, mg/dL | 40 | 6-516 |
| MYD88 mutations | 52/57 | 91.2% |
| CXCR4 mutations | 23/57 | 40.0% |
| ARID1A mutations | 5/51 | 9.8% |
| CD79B mutations | 4/51 | 7.8% |
| Deletion chromosome 6q | 24/53 | 45.3% |
| Amplification chromosome 6p | 6/53 | 11.3% |
| Amplification chromosome 3q | 11/52 | 19.2% |
| Amplification chromosome 4 | 10/52 | 21.1% |
| . | Median or count . | Range or percentage . |
|---|---|---|
| Sex, female | 21/57 | 36.8% |
| Age at diagnosis, y | 60 | 40-78 |
| β2 microglobulin at diagnosis >3, mg/L | 19/46 | 41.3% |
| Age at biopsy, y | 62 | 41-83 |
| Familial history of WM | 3/57 | 5.3% |
| Splenomegaly | 13/57 | 22.8% |
| Lymphadenopathy | 30/57 | 52.6% |
| Bone marrow involvement, % | 60 | 5-95 |
| Hemoglobin, g/dL | 11.1 | 8.2-14.5 |
| Serum IgM, mg/dL | 3750 | 416-8320 |
| Serum IgG, mg/dL | 517 | 82-3890 |
| Serum IgA, mg/dL | 40 | 6-516 |
| MYD88 mutations | 52/57 | 91.2% |
| CXCR4 mutations | 23/57 | 40.0% |
| ARID1A mutations | 5/51 | 9.8% |
| CD79B mutations | 4/51 | 7.8% |
| Deletion chromosome 6q | 24/53 | 45.3% |
| Amplification chromosome 6p | 6/53 | 11.3% |
| Amplification chromosome 3q | 11/52 | 19.2% |
| Amplification chromosome 4 | 10/52 | 21.1% |